Literature DB >> 8839479

Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro.

M C Truss1, S Uckert, C G Stief, W G Forssmann, U Jonas.   

Abstract

Phosphodiesterases (PDEs) regulate intracellular cyclic nucleotide metabolism and, thus, contraction and relaxation of smooth musculature. The aim of the present study was to evaluate the functional effects of isoenzyme-selective inhibitors and their effects on cyclic nucleotide levels in the human detrusor smooth muscle. In addition, the functional relevance of the cAMP versus the cGMP pathways in the regulation of the detrusor smooth muscle tone was assessed. Relaxant responses to various PDE inhibitors, forskolin and sodium nitroprusside (SNP) were investigated in vitro using a standard organ bath setup. Cyclic nucleotide levels were measured after incubation with the same substances using cAMP and cGMP radioimmunoassays (RIAs). Significant relaxant responses were only induced by non-selective PDE inhibition, the PDE I inhibitor vinpocetine and the adenylate cyclase activator forskolin. Relaxant responses to these substances were paralleled by increases in cyclic nucleotide levels. Our data suggest that the cAMP pathway and calcium/calmodulin-stimulated PDE (PDE I) may be of functional importance in the regulation of the human detrusor smooth muscle tone in vitro.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8839479     DOI: 10.1007/bf00304075

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  16 in total

1.  Flavoxate, a potent phosphodiesterase inhibitor.

Authors:  M Conti; I Setnikar
Journal:  Arch Int Pharmacodyn Ther       Date:  1975-02

Review 2.  Cyclic GMP and mechanisms of vasodilation.

Authors:  T M Lincoln
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

Review 3.  Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma.

Authors:  C D Nicholson; M Shahid
Journal:  Pulm Pharmacol       Date:  1994-02

4.  Comparison of the effects of forskolin and isoproterenol on cyclic AMP levels and tension in bovine coronary artery.

Authors:  R V Vegesna; J Diamond
Journal:  Can J Physiol Pharmacol       Date:  1983-10       Impact factor: 2.273

Review 5.  Cyclic nucleotides and regulation of vascular smooth muscle.

Authors:  J G Hardman
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

6.  Regional difference in functional roles of cAMP and cGMP in lower urinary tract smooth muscle contractility.

Authors:  T Morita; T Tsujii; S Dokita
Journal:  Urol Int       Date:  1992       Impact factor: 2.089

Review 7.  The role of phosphodiesterase inhibitors in heart failure.

Authors:  J M Arnold
Journal:  Pharmacol Ther       Date:  1993 Feb-Mar       Impact factor: 12.310

8.  Nitric oxide and relaxation of pig lower urinary tract.

Authors:  K Persson; K E Andersson
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

9.  Effects of inhibition of the L-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro.

Authors:  K Persson; Y Igawa; A Mattiasson; K E Andersson
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

10.  Protective action of vinpocetine against experimentally induced gastric damage in rats.

Authors:  V Nosálová; J Machová; A Babulová
Journal:  Arzneimittelforschung       Date:  1993-09
View more
  20 in total

1.  An investigation of the effects of zaprinast, a PDE inhibitor, on the nitrergic control of the urethra in anaesthetized female rats.

Authors:  Alexandra Wibberley; Philip A Nunn; Alasdair M Naylor; Andrew G Ramage
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 2.  Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.

Authors:  Stefan Uckert; Christian G Stief; Margit Mayer; Udo Jonas; Petter Hedlund
Journal:  World J Urol       Date:  2005-12-06       Impact factor: 4.226

Review 3.  Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences.

Authors:  Emilio Sacco; Francesco Pinto; Pierfrancesco Bassi
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-01-15

4.  [Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study].

Authors:  S Uckert; K Sigl; E S Waldkirch; P Sandner; E Ulbrich; M Oelke; C G Stief; M A Kuczyk
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

5.  Phosphodiesterase type 2 distribution in the guinea pig urinary bladder.

Authors:  M S Rahnama'i; R Hohnen; Ph E V Van Kerrebroeck; G A van Koeveringe
Journal:  World J Urol       Date:  2014-12-06       Impact factor: 4.226

6.  Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.

Authors:  Honglin Ding; Ning Li; Xiaoning He; Bing Liu; Liming Dong; Yili Liu
Journal:  Int Urol Nephrol       Date:  2017-07-29       Impact factor: 2.370

Review 7.  The role of phosphodiesterases in bladder pathophysiology.

Authors:  Mohammad S Rahnama'i; Stefan Ückert; Ramona Hohnen; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

8.  Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Hartmut Porst; Peter Sandner; Ernst Ulbrich
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 9.  Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review.

Authors:  Ching-Shwun Lin; Maarten Albersen; Zhongcheng Xin; Mikio Namiki; Dieter Muller; Tom F Lue
Journal:  Urology       Date:  2013-01-17       Impact factor: 2.649

10.  Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization.

Authors:  M C Truss; S Uckert; C G Stief; M Kuczyk; U Jonas
Journal:  Urol Res       Date:  1996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.